Is EPRXF or DVY a better dividend investment in 2026?

EPRXF currently yields 65.79% with a 5% 5-year dividend growth rate. DVY yields 3.46% with 5% growth. The better choice depends on your goal: EPRXF offers higher current income.

What is the dividend yield difference between EPRXF and DVY?

EPRXF has a forward dividend yield of 65.79% ($2.00/share annually). DVY yields 3.46% ($5.25/share annually). The yield gap is 62.33 percentage points.

Home › Compare › EPRXF vs DVY

EPRXF vs DVY: Dividend Comparison 2026

EPRXF yields 65.79% · DVY yields 3.46%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EPRXF wins by $836.9K in total portfolio value

INVESTMENT

TIME HORIZON10 years

EPRXF

● Live price

65.79%

Share price

$3.04

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$861.9K

Annual income

$216,014.89

Full EPRXF calculator →

DVY

● Live price

3.46%

Share price

$151.41

Annual div

$5.25

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.0K

Annual income

$432.91

Full DVY calculator →

Portfolio growth — EPRXF vs DVY

📍 EPRXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EPRXF	DVY
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EPRXF + DVY cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EPRXF pays

DVY pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPRXF

Annual income on $10K today (after 15% tax)

$5,592.11/yr

After 10yr DRIP, annual income (after tax)

$183,612.66/yr

DVY

Annual income on $10K today (after 15% tax)

$294.47/yr

After 10yr DRIP, annual income (after tax)

$367.97/yr

At 15% tax rate, EPRXF beats the other by $183,244.68/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPRXF + DVY for your $10,000?

EPRXF: 50%DVY: 50%

100% DVY50/50100% EPRXF

Portfolio after 10yr

$443.5K

Annual income

$108,223.90/yr

Blended yield

24.40%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPRXF buys

DVY buys

No recent congressional trades found for EPRXF or DVY in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEPRXFDVY

Forward yield	65.79% ✓	3.46%
Annual dividend / share	$2.00	$5.25 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$861.9K ✓	$25.0K
Annual income after 10y	$216,014.89 ✓	$432.91
Total dividends collected	$726.7K ✓	$3.9K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: EPRXF vs DVY ($10,000, DRIP)

Year	EPRXF Portfolio	EPRXF Income/yr	DVY Portfolio	DVY Income/yr	Gap
1← crossover	$17,279	$6,578.95	$11,046	$346.43	+$6.2K → EPRXF
2	$29,113	$10,624.05	$12,177	$357.65	+$16.9K → EPRXF
3	$47,879	$16,728.95	$13,398	$368.47	+$34.5K → EPRXF
4	$76,944	$25,713.03	$14,715	$378.89	+$62.2K → EPRXF
5	$120,949	$38,618.52	$16,134	$388.90	+$104.8K → EPRXF
6	$186,148	$56,733.31	$17,662	$398.51	+$168.5K → EPRXF
7	$280,783	$81,604.23	$19,306	$407.71	+$261.5K → EPRXF
8	$415,475	$115,037.79	$21,074	$416.50	+$394.4K → EPRXF
9	$603,645	$159,085.84	$22,974	$424.90	+$580.7K → EPRXF
10	$861,915	$216,014.89	$25,015	$432.91	+$836.9K → EPRXF

EPRXF vs DVY: Complete Analysis 2026

EPRXF — Stock

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Full EPRXF Calculator →

DVY — ETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →

📬

Get this EPRXF vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPRXF vs SCHD EPRXF vs JEPI EPRXF vs O EPRXF vs KO EPRXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.